New drug duo aims to halt cervical cancer growth
NCT ID NCT06266338
First seen Jan 10, 2026 · Last updated Apr 25, 2026 · Updated 18 times
Summary
This study tests whether combining two drugs, pembrolizumab and lenvatinib, can slow or stop tumor growth in women with cervical cancer that has returned or spread. About 30 participants will receive the treatment to see if tumors shrink or stabilize. The goal is to find a better option for those who have already tried other therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.